Therefore, we conclude that the regulation of corneal NV by Zeb1 is independent of VEGF and the ZEB1-CtBP inhibitor, NCS95397, may have the therapeutic potential for ocular NV and possible cancers. Here, ZEB1 is linked to cancer.